アブストラクト
| Title | 第24回 ADHD治療薬の特徴とリスデキサンフェタミン |
|---|---|
| Subtitle | 連載 児童精神科医が伝えたい 子どものメンタルヘルス |
| Authors | 宇佐美政英 |
| Authors (kana) | |
| Organization | 国立国際医療研究センター国府台病院子どものこころ総合診療センター長 / 児童精神科 診療科長 |
| Journal | 月刊薬事 |
| Volume | 64 |
| Number | 1 |
| Page | 158-165 |
| Year/Month | 2022 / 1 |
| Article | 報告 |
| Publisher | じほう |
| Abstract | 「坊っちゃん」前回の太宰治の『人間失格』に続いて, 夏目漱石の『坊っちゃん』, 『こころ』, 『それから』, 『三四郎』を読みました. 誰もが知る夏目漱石は1867年生まれで1916年没, 明治時代を生きた文豪の一人です. 作家としては38歳に『吾輩は猫である』でデビューしており, その後12年ほどしか活動していません. 漱石という名前は中国の故事「漱石枕流」から取られていますが, この言葉は負け惜しみを言ったり自説を無理に通そうとする態度を表しています. 私が勝手に抱いていた夏目漱石のイメージ(聖人君子な人柄)とは何だか違っているように思いました. 小学校の頃など, きれいな日本語を書く代表的な作家として夏目漱石を勧められ, しっかり読むように教え込まれた記憶がありますが, 大人になって「漱石」の意味を知ると, これはこれで人間味があって親しみやすい印象を受けます. |
| Practice | 薬学 |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に803円(税込) です。
参考文献
- 1) 夏目漱石:坊っちゃん. 新潮社(新潮文庫), 1950
- 2) Still GF:The Goulstonian lectures on some abnormal psychical conditions in children. Lancet, 159:1008-1013, 1902
- 3) 齊藤万比古・編:注意欠如・多動症-ADHD-の診断・治療ガイドライン 第4版(齊藤万比古・編). じほう, 2016
- 4) Atkinson M, et al:NICE guideline:attention deficit peractivity disorder. Arch Dis Child Educ Pract Ed, 95:24-27, 2010
- 5) Cortese S, et al:Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults:a systematic review and network meta-analysis. Lancet Psychiatry, 5:727-738, 2018
残りの21件を表示する
- 6) Schachter HM, et al:How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ, 165:1475-1488, 2001
- 7) Barbaresi WJ, et al:Long-term stimulant medication treatment of attention-deficit/hyperactivity disorder:results from a population-based study. J Dev Behav Pediatr, 27:1-10, 2006
- 8) A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry, 56:1073-1086, 1999
- 9) Okumura Y, et al:Prevalence, incidence and persistence of ADHD drug use in Japan. Epidemiol Psychiatr Sci, 28:692-696, 2019
- 10) Beau-Lejdstrom R, et al:Latest trends in ADHD drug prescribing patterns in children in the UK:prevalence, incidence and persistence. BMJ Open, 6:e010508, 2016
- 11) Furu K, et al:Utilization of Stimulants and Atomoxetine for Attention-Deficit/Hyperactivity Disorder among 5.4 Million Children Using Population-Based Longitudinal Data. Basic Clin Pharmacol Toxicol, 120:373-379, 2017
- 12) Bachmann CJ, et al:ADHD in Germany:Trends in Diagnosis and Pharmacotherapy. Dtsch Arztebl Int, 114:141-148, 2017
- 13) Biederman J, et al:Is ADHD a risk factor for psychoactive substance use disorders? Findings from a four-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry, 36:21-29, 1997
- 14) Wilens TE, et al:A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry, 51:74-85, 2012
- 15) Dittmann RW, et al:Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder:a head-to-head, randomized, double-blind, phase IIIb study. CNS Drugs, 27:1081-1092, 2013
- 16) Newcorn JH, et al:Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder. CNS Drugs, 31:999-1014, 2017
- 17) Katic A, et al:Treatment outcomes with lisdexamfetamine dimesylate in children who have attention-deficit/hyperactivity disorder with emotional control impairments. J Child Adolesc Psychopharmacol, 23:386-393, 2013
- 18) Schneider E, et al:Lisdexamfetamine and binge-eating disorder:A systematic review and meta-analysis of the preclinical and clinical data with a focus on mechanism of drug action in treating the disorder. Eur Neuropsychopharmacol, 53:49-78, 2021
- 19) Agh T, et al:The Cost Effectiveness of Lisdexamfetamine Dimesylate for the Treatment of Binge Eating Disorder in the USA. Clin Drug Investig, 36:305-312, 2016
- 20) Sasaki Y, et al:Current use of attention-deficit hyperactivity disorder(ADHD) medications and clinical characteristics of child and adolescent psychiatric outpatients prescribed multiple ADHD medications in Japan. PLoS One, 16:e0252420, 2021
- 21) Antshel KM, et al:An update on the comorbidity of ADHD and ASD:a focus on clinical management. Expert Rev Neurother, 16:279-293, 2016
- 22) Sturman N, et al:Methylphenidate for children and adolescents with autism spectrum disorder. Cochrane Database Syst Rev, 11:CD011144, 2017
- 23) Hughes K, et al:The effect of multiple adverse childhood experiences on health:a systematic review and meta-analysis. Lancet Public Health, 2:e356-e366, 2017
- 24) Yu R, et al:Depression and Violence in Adolescence and Young Adults:Findings From Three Longitudinal Cohorts. J Am Acad Child Adolesc Psychiatry, 56:652-658, 2017
- 25) Retz W, et al:Association of ADHD with reactive and proactive violent behavior in a forensic population. Atten Defic Hyperact Disord, 2:195-202, 2010
- 26) Sugama M, et al:Drug therapy for AD/HD investigation of usefulness of extended-release methylphenidate and atomoxetine from the viewpoint of persistency rate. No To Hattatsu, 46:22-25, 2014
